142 related articles for article (PubMed ID: 37914086)
1. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J
Kidney Int; 2024 Jan; 105(1):189-199. PubMed ID: 37914086
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J
Kidney Int Rep; 2023 May; 8(5):968-979. PubMed ID: 37180505
[TBL] [Abstract][Full Text] [Related]
3. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Bomback AS; Kavanagh D; Vivarelli M; Meier M; Wang Y; Webb NJA; Trapani AJ; Smith RJH
Kidney Int Rep; 2022 Oct; 7(10):2150-2159. PubMed ID: 36217526
[TBL] [Abstract][Full Text] [Related]
4. Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.
Vivarelli M; Bomback AS; Meier M; Wang Y; Webb NJA; Veldandi UK; Smith RJH; Kavanagh D
Kidney Int Rep; 2024 Jan; 9(1):64-72. PubMed ID: 38312795
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
[TBL] [Abstract][Full Text] [Related]
6. A new alternative: inhibiting complement activation in patients with IgA nephropathy.
Floege J
Kidney Int; 2024 Jan; 105(1):28-30. PubMed ID: 38182298
[TBL] [Abstract][Full Text] [Related]
7. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
8. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
9. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
Barratt J; Liew A; Yeo SC; Fernström A; Barbour SJ; Sperati CJ; Villanueva R; Wu MJ; Wang D; Borodovsky A; Badri P; Yureneva E; Bhan I; Cattran D;
Clin J Am Soc Nephrol; 2024 Apr; 19(4):452-462. PubMed ID: 38214599
[TBL] [Abstract][Full Text] [Related]
11. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J; Lafayette R; Kristensen J; Stone A; Cattran D; Floege J; Tesar V; Trimarchi H; Zhang H; Eren N; Paliege A; Rovin BH;
Kidney Int; 2023 Feb; 103(2):391-402. PubMed ID: 36270561
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Wong E; Nester C; Cavero T; Karras A; Le Quintrec M; Lightstone L; Eisenberger U; Soler MJ; Kavanagh D; Daina E; Praga M; Medjeral-Thomas NR; Gäckler A; Garcia-Carro C; Biondani A; Chaperon F; Kulmatycki K; Milojevic J; Webb NJA; Nidamarthy PK; Junge G; Remuzzi G
Kidney Int Rep; 2023 Dec; 8(12):2754-2764. PubMed ID: 38106570
[TBL] [Abstract][Full Text] [Related]
13. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
14. C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.
Bruchfeld A; Magin H; Nachman P; Parikh S; Lafayette R; Potarca A; Miao S; Bekker P
Clin Kidney J; 2022 May; 15(5):922-928. PubMed ID: 35498891
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
16. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Lafayette R; Barbour S; Israni R; Wei X; Eren N; Floege J; Jha V; Kim SG; Maes B; Phoon RKS; Singh H; Tesař V; Lin CJF; Barratt J
Kidney Int; 2024 Jun; 105(6):1306-1315. PubMed ID: 38552841
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
Am J Nephrol; 2021; 52(10-11):827-836. PubMed ID: 34731857
[TBL] [Abstract][Full Text] [Related]
19. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
20. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA
Chiu YL; Lin WC; Shu KH; Fang YW; Chang FC; Chou YH; Wu CF; Chiang WC; Lin SL; Chen YM; Wu MS
Front Immunol; 2021; 12():638309. PubMed ID: 34177889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
